Fact:
These products are reviewed by the FDA for quality, safety, and effectiveness.
Myth:
Compounded GLP-1s are just cheaper versions of the same thing
Fact:
They are not FDA-approved, can contain impurities, and may not have the right dose.
GLP-1 medications have been studied extensively, and the evidence supporting their effectiveness continues to grow. Depending on the specific FDA-approved medicine and indication, these therapies can support chronic weight management, improve blood sugar control, and provide additional health benefits.
Beyond weight management, FDA-approved GLP-1 medicines now have important indications for other serious health conditions. Wegovy (semaglutide) is approved to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults with cardiovascular disease and overweight or obesity. Wegovy injection is also approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis in adults. Zepbound (tirzepatide) is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
These expanding indications show that GLP-1 medicines are used to treat serious chronic health conditions—not simply for weight loss. Patients should use FDA-approved medicines when available and work with a licensed health care professional to determine which treatment is appropriate for their individual medical needs.
Don’t fall for fakes. Follow the facts.
Before you buy, verify!
Quality You Can Trust vs. Gambles You Can't!
Your Health Deserves the Real Thing!
Don’t fall for fakes. Follow the facts.
Before you buy, verify!
Quality You Can Trust vs. Gambles You Can't!
Your Health Deserves the Real Thing!
Sources: National Consumers League, Washington Informer, AP News, WSJ,
Counterfeit or illegally marketed weight-loss drugs may contain the wrong ingredient, an incorrect amount of medicine, or harmful contaminants. Products from unverified sources may also have misleading labels, unsafe storage conditions, or unclear dosing instructions. Use prescription GLP-1 medicines only under the care of a licensed health care professional and obtain them from a licensed pharmacy.
FDA-approved GLP-1 medicines have been reviewed by the FDA for safety, effectiveness, quality, and manufacturing standards. Compounded GLP-1 medicines are not FDA-approved and are not reviewed by the FDA before they are marketed for safety, effectiveness, or quality. Compounded medicines may be appropriate for certain patients with a specific medical need that cannot be met by an available FDA-approved drug.
Ask why a compounded medicine is being recommended and whether an FDA-approved option can meet your medical needs. Compounded drugs can serve an important medical need for some patients, but they are not FDA-approved. If a compounded GLP-1 is prescribed, make sure it is filled by a properly licensed pharmacy and ask about the ingredients, dose, storage, and how to use it safely.
Avoid buying prescription GLP-1 medicines from social media sellers or websites that cannot be verified as legitimate pharmacies. Products from unlicensed or unverified sellers may be counterfeit, contaminated, improperly stored, or contain the wrong ingredients or dose. Get a prescription from a licensed health care professional and fill it through a state-licensed pharmacy.
Dec 2024:
FDA re-evaluated its earlier decision and determined that the tirzepatide injection shortage was resolved. Temporary enforcement-discretion periods were provided for certain compounders to reduce treatment disruption.
Feb 2025:
FDA determined that the semaglutide injection shortage was resolved and provided temporary enforcement-discretion periods for certain compounders.
Feb–May 2025:
FDA’s temporary enforcement-discretion periods ended in stages. For tirzepatide, all temporary enforcement-discretion periods had ended by March 19, 2025. For semaglutide, they had ended by May 22, 2025.
Sept 2025:
FDA launched a “Green List” import alert to help prevent GLP-1 active pharmaceutical ingredients with potential quality concerns from unverified foreign sources from entering the U.S. supply chain, while allowing imports from compliant manufacturers.
March 2026:
FDA issued warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products.
April 2026:
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
May 31, 2026:
FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
July 2026:
CMS launched the Medicare GLP-1 Bridge, providing eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management with a $50 monthly copay. The program runs through December 31, 2027.
July 2026:
The Senate HELP Committee advanced the bipartisan SAFE Drugs Act of 2026 (S. 3794) by a 17–5 vote. The bill would strengthen transparency and reporting requirements for compounded medications, including serious adverse-event reporting and clearer labeling. On July 27, 2026, the bill was reported to the Senate and placed on the Senate Legislative Calendar under General Orders, Calendar No. 524. It has not yet passed the full Senate.
Compounded GLP-1 medicines are not FDA-approved and may only be prepared under specific legal conditions. In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
Bulk API from unverified foreign suppliers can be detained at the border; products labeled “research use only/not for human use” are not appropriate for patients.
Salt forms such as semaglutide sodium or semaglutide acetate are different active ingredients from the semaglutide used in FDA-approved medicines. FDA has said it is not aware of a lawful basis for using these salt forms in compounded drugs and has raised concerns about their safety and effectiveness.
